|
#31
14.10.2011, 19:40
|
||||
|
||||
|
è åùå, çäåñü ïî ññûëêå
Effect of Omacor on HRV parameters in patients with recent uncomplicated myocardial infarction - A randomized, parallel group, double-blind, placebo-controlled trial: study design [ISRCTN75358739]. Pater C, Compagnone D, Luszick J, Verboom CN. SourceDepartment of Cardiovascular Clinical Development, Solvay Pharmaceuticals GmbH, Hannover, Germany. [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] óòâåðæäàåòñÿ, ÷òî ÃÈÑÑÈ ñäåëàíî íà ñîëâååâñêîì Îìàêîðå: Results of the GISSI-Prevenzione study [34] (11,323 patients with recent myocardial infarction randomized to Omacor or vitamin E or the combination of the two) showed significantly lower all-cause mortality in the Omacor group, resulting largely from a 45% reduction in sudden cardiac death during 3.5 years of follow-up. 
|
|
#32
14.10.2011, 19:43
|
||||
|
||||
|
Öèòàòà:
Ïðî ðòóòü, êîíå÷íî, äà. Íî îìàêîð îò Ýááîò (áûâø. Ñîëâàé) â ÐÔ íåîïðàâäàíî äîðîã. Ïðè ýòîì ïàðàëëåëüíî ïðîäàþòñÿ ÁÀÄ îò ïðèëè÷íûõ ïðîèçâîäèòåëåé (ò.å. áåç ðòóòè) ñ åùå áÎëüøèì ñîäåðæàíèåì ÏÍÆÊ, íî ñóùåñòâåííî äåøåâëå. Ìíå êàæåòñÿ, ÷òî ëó÷øå ýòè 1300ð. â ìåñÿö (à åñëè êàê íàäî 4 ãðàììà, òî õ 4 = 5200ð.), ïîòðàòèòü íà áîëåå EBM ëåêàðñòâà.
|
|
#33
14.10.2011, 19:47
|
||||
|
||||
|
ñîñòàâ èäåíòè÷íûé ó Ëîâàçû è Îìàêîðà, íåèçâåñòíî òîëüêî èç îäíîé áî÷êè èëè ïðîñòî èäåíòè÷íî äåëàþò, ïîíÿòíî, ÷òî íå Reliant ïðèäóìàë òàêóþ êîìáèíàöèþ, ïîòîìó êàê ïóáëèêàöèè î íåì â íîðìàëüíîé ïåðèîäèêå ïîÿâèëèñü ãîðàçäî ïîçæå, ÷åì ðåçóëüòàòû òîãî æå 3-4 ëåòíåãî ÃÈÑÑÈ:
Am J Cardiol. 2006 Aug 21;98(4A):71i-76i. Clinical overview of Omacor: a concentrated formulation of omega-3 polyunsaturated fatty acids. Bays H. SourceL-MARC Research Center, Louisville, Kentucky 40213, USA. Abstract Omacor (omega-3-acid ethyl esters; Reliant Pharmaceuticals, Inc., Liberty Corner, NJ) is a highly purified, prescription omega-3 fatty acid formulation with high concentrations of eicosapentaenoic acid (EPA) (465 mg) and docosahexaenoic acid (DHA) (375 mg) in each 1-g capsule, along with 4 mg (6 IU) of vitamin E. At a typical dose of 4 capsules/day, Omacor significantly lowers plasma triglyceride levels either as monotherapy or in combination with 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) or fibrates. Omacor also modestly increases plasma levels of low-density lipoprotein cholesterol, increases high-density lipoprotein cholesterol levels, and has favorable effects on lipoprotein particle size and subclass distribution. Omacor is well tolerated, with few side effects other than mild gastrointestinal symptoms. Hyperglycemia, abnormal bleeding, elevations in muscle or liver enzymes, and/or abnormalities in kidney or nerve function have not been reported. Through its intensive purification process, Omacor has minimal "fishy" smell and taste, and it has not been reported to cause hypervitaminosis or illness due to exposure to environmental toxins. Omacor provides a safe, effective, well-tolerated approach to management of hypertriglyceridemia.
|
|
#34
14.10.2011, 19:55
|
||||
|
||||
|
Ýòî Âû åùå öåíó íà Ëîâàçó íå âèäåëè: 120 êàïñóë ïî 1 ã 180 ÓÑÄ, äëÿ ñðàâíåíèÿ
Fish Oil Concentrate 1200 mg, Omega 3 EPA (Eicosapentaenoic Acid)(as ethyl esters) 410 mg, Omega 3 DHA (Docosahexaenoic Acid (as ethyl esters) 274 mg - 180 Softgels - $16.99 10(!!!)êðàòíàÿ ðàçíèöà â öåíå ïðè òîì ÷òî äàþò â ïîëòîðà ðàçà áîëüøå êàïñóë, â êîòîðûõ îìåãè òîëüêî íà 10-15% ìåíüøå, ÷åì â Ëîâàçå... Ïîäîçðåâàþ, ÷òî ïðîèçâîäèòåëè ÁÀÄîâ ïðîñòî íå ìîãóò èç-çà ïàòåíòà ïðîèçâîäèòü èäåíòè÷íóþ (â ìã è ñîîòíîøåíèè 46:38) Ëîâàçå îìåãó, ñðîê êîòîðîãî èñòåêàåò íå òî â 2013, íå òî â 2015 ãîäó
|
|
#35
14.10.2011, 19:56
|
||||
|
||||
|
Öèòàòà:
Ïðè ýòîì îò÷åò ñàìîãî èññëåäîâàíèÿ íå ñîäåðæèò òîðãîâûõ íàçâàíèé, à ñëîâî äîáàâêè â ìíîæåñòâåííîì ÷èñëå (ò.å. ðàçíûå?): [Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] METHODS: From October, 1993, to September, 1995, 11,324 patients surviving recent (< or = 3 months) myocardial infarction were randomly assigned supplements of n-3 PUFA (1 g daily, n=2836), vitamin E (300 mg daily, n=2830), both (n=2830), or none (control, n=2828) for 3.5 years. The primary combined efficacy endpoint was death, non-fatal myocardial infarction, and stroke. Intention-to-treat analyses were done according to a factorial design (two-way) and by treatment group (four-way). Ìîæåò Ñîëâàé ñ èõ íàâÿç÷èâîé ïðîìîöèåé ñàìè ïîâåðèëè â òî, ÷åãî íå áûëî?
|
|
#36
14.10.2011, 20:01
|
||||
|
||||
|
Öèòàòà:
|
|
#37
14.10.2011, 20:07
|
||||
|
||||
|
Çàëåç â ïîëíûé òåêñò ÃÈÑÑÈ: âîò ÷òî òàì
In the absence of evidence for preferred doses of treatments, we decided on the daily doses of n-3 PUFA as 1 gelatin capsule containing 850–882 mg eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethyl esters in the average ratio of EPA/DHA 1:2... è â êîíöå This study was supported by grants from Bristol-Myers Squibb, Pharmacia-Upjohn, Società Prodotti Antibiotici, and Pfizer. Pharmacia-Upjohn and Società Prodotti Antibiotici supplied marketed capsules containing 850–882 mg EPA/DHA ethyl esters. êàêîâà ñóäüáà Pharmacia-Upjohn íå çíàåòå? íàøåë - êóïèëè Ïôàéçåð â 2002...
|
|
|
|
#38
14.10.2011, 20:16
|
||||
|
||||
|
 GISSI Prevenzione æåëåçîáåòîííî áûë íå Îìàêîð!
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] Ãðóïïà ñðàâíåíèÿ äëÿ n-3 PUFA - Âèòàìèí Å, à â îìàêîðå âèòàìèí Å âõîäèò â ñîñòàâ (4 ìã). we decided on the daily doses of n-3 PUFA as 1 gelatin capsule containing 850–882 mg eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) as ethyl esters in the average ratio of EPA/DHA 1:2, and 300 mg vitamin E, given as one capsule of synthetic α-tocopherol Äà è ñîñòàâ íå ñîâïàäàåò: in the average ratio of EPA/DHA 1:2 38 ê 46 - òî÷íî íå 1 ê 2!! 
|
|
#39
14.10.2011, 20:18
|
||||
|
||||
|
Öèòàòà:
Êàê íå ñòûäíî áûëî Ñîëâåþ âðàòü, ÷òî ýòî èññëåäîâàíèå íà èõ ïðåïàðàòå???
|
|
#40
14.10.2011, 20:25
|
||||
|
||||
|
Àãà, íàøåë, Âû áûëè ïðàâû: Ñîëâýé ïåðåêóïèë â 2005 ïðàâà íà Îìàêîð ó Ïðîíîâû Áèî èç Øâåöèè, êîòîðàÿ òàêæå ïðîäàëà ïðàâà Reliant íà åãî ðàñïðîñòðàíåíèå â Øòàòàõ, íå èñêëþ÷åíî ÷òî ó Ïðîíîâû áûëè (âðåìåííûå?) ïàðòíåðñêèå ñâÿçè ñî øâåäñêîé Ôàðìàöèÿ, êîòîðàÿ ñïîíñèðîâàëà ÃÈÑÑÈ...
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ] òàê ÷òî ïðîèçâîäèòåëü-ðàçðàáîò÷èê îäèí...
|
|
#41
14.10.2011, 20:31
|
||||
|
||||
|
äóìàþ, ó èòàëüÿíöåâ â îðèãèíàëå èëè îïèñêà (âìåñòî 1:1.2 ïðîñêî÷èëî â ïå÷àòü 1:2) èëè èõ Ôàðìàöèÿ ââåëà â çàáëóæäåíèå, òàêæå âèäíî, ÷òî âî âðåìåíà áûëûõ òåõíîëîãèé íå âñåãäà óäàâàëîñü äåðæàòü òî÷íóþ êîíöåíòðàöèþ îìåãè â 1 ã âîò è ñêàêàëà 850-880, à òåïåðü æåëåçíî 465:375 èëè 840
|
|
#42
14.10.2011, 20:36
|
||||
|
||||
|
Öèòàòà:
Íå óâåðåí â èäåíòè÷íîñòè ïðåïàðàòîâ. Ïîòîìó è àìåðèêàíöû ñ Ëîâàçîé íå óïîìÿíàþò î GISSI. ÃÑÊ - ÷åñòíåå Ñîëâàÿ Ñîñòàâ, ñêîðåå âñåãî, ìåíÿëè ïîä íóæäû ïðîèçâîäñòâà. Îäíèì áûëî óäîáíåå ôàñîâàòü òàêóþ ïðîïîðöèþ, äðóãèì - äðóãóþ.
|
|
#43
14.10.2011, 20:41
|
||||
|
||||
|
òóò åùå òàêàÿ ïðîáëåìà: ÷òîá ïðîéòè ÷åðåç ÔÄÀ àêêðåäèòàöèþ òðåáóþò, ÷òîáû ëåêàðñòâî òåñòèðîâàëîñü íà àìåðèêàíöàõ, òàê ÷òî èòàëüÿíñêîå ÃÈÑÑÈ ó ÔÄÀ íå ïðîéäåò, äàæå åñëè áûë è èäåíòè÷íûé ïðåïàðàò...
ÿ èìåë â âèäó, ÷òî íûíåøíÿÿ Ëîâàçà è Îìàêîð - îäíîãî ïîëÿ ÿãîäû, ÷òî èìåííî áûëî â ÃÈÑÑÈ ñåé÷àñ óæå íå ðàçîáðàòü...
|
|
#44
25.12.2011, 09:04
|
|||
|
|||
|
Ìíå ïîñòîÿííî ïðèõîäèò ðàññûëêà, ÷òî Îìàêîð îäîáðåí ÂÎÇ ê òåðàïèè ÕÑÍ ,î÷åðåäíîé ðåêëàìíûé õîä?
[Ññûëêè äîñòóïíû òîëüêî çàðåãèñòðèðîâàííûì ïîëüçîâàòåëÿì ]
|
Ëèíåéíûé âèä
